Home Alzheimer’s Disease Michael J. Morris, MD on the Impact of PyL-PET/CT Scans on the...

Michael J. Morris, MD on the Impact of PyL-PET/CT Scans on the Clinical Management of Patients With Prostate Cancer

Results from the phase III CONDOR trial, presented during the 2020 ASCO Virtual Scientific Program, showed that prostate specific membrane antigen (PSMA) 18F-DCFPyL-positron emission tomography (PET) scans demonstrated a correct localization rate (CLR) of 84.8-87.0% per 3 blinded independent readers, meeting the trial’s primary endpoint.

In an interview with CancerNetwork, Michael J. Morris, MD, prostate cancer section head at Memorial Sloan Kettering Cancer Center discussed a secondary endpoint of the trial – the change in treatment plans and patient care after completion of the scans.

 

Transcription:

So, the clinicians completed a questionnaire both before and after the performance of the PSMA scan to see if the PSMA scan changed their management. In 20% of those patients, that change in management was a change in goal of care, from a non-curative systemic therapy-based…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

32 year old singer Tom Parker of The Wanted diagnosed with stage 4 glioblastoma

submitted by /u/Jexlan Continue Reading to the Source

Recent Comments